News
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...
Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.
